These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 35330441)

  • 1. Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland.
    Reymann S; Schoretsanitis G; Egger ST; Mohonko A; Kirschner M; Vetter S; Homan P; Seifritz E; Burrer A
    J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the impact of long-acting injectable compared to oral antipsychotic medications on readmission to a state psychiatric hospital.
    Okoli CTC; Abufarsakh B; Wang T; Makowski A; Cooley A
    J Psychiatr Ment Health Nurs; 2024 Jun; ():. PubMed ID: 38922793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
    Doshi JA; Pettit AR; Stoddard JJ; Zummo J; Marcus SC
    J Clin Psychopharmacol; 2015 Aug; 35(4):442-6. PubMed ID: 26075492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders.
    Boyer L; Falissard B; Nuss P; Collin C; Duret S; Rabbani M; De Chefdebien I; Tonelli I; Llorca PM; Fond G
    Mol Psychiatry; 2023 Sep; 28(9):3709-3716. PubMed ID: 37479781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
    Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations.
    Liu Y; Patterson ME; Sahil S; Stoner SC
    Front Pharmacol; 2023; 14():1140969. PubMed ID: 37284307
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of Long-Acting Injectable Antipsychotic in an Inpatient Unit of a Community Teaching Hospital.
    Olayinka O; Oyelakin A; Cherukupally K; Virk I; Ojimba C; Khadka S; Maksymenko A; Fouron P; Khandaker T; Olupona T; Hershberger J
    Psychiatry J; 2019; 2019():8629030. PubMed ID: 31312652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
    Maestri TJ; Mican LM; Rozea H; Barner JC
    Psychopharmacol Bull; 2018 Mar; 48(3):8-15. PubMed ID: 29713100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
    Joshi K; Pan X; Wang R; Yang E; Benson C
    Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia.
    Potkin S; Bera R; Zubek D; Lau G
    BMC Psychiatry; 2013 Oct; 13():261. PubMed ID: 24131801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study.
    Llorca PM; Bobes J; Fleischhacker WW; Heres S; Moore N; Bent-Ennakhil N; Sapin C; Loze JY; Nylander AG; Patel MX
    Eur Psychiatry; 2018 Aug; 52():85-94. PubMed ID: 29734130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics on Time to Rehospitalization Within 1 Year of Discharge in Elderly Patients With Schizophrenia.
    Lin CH; Chen FC; Chan HY; Hsu CC
    Am J Geriatr Psychiatry; 2020 Jan; 28(1):23-30. PubMed ID: 31481273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey.
    Zhdanava M; Starr HL; Lefebvre P; Totev TI; Shah A; Sheng K; Pilon D
    Neuropsychiatr Dis Treat; 2022; 18():1479-1493. PubMed ID: 35910684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attitudes of European physicians towards the use of long-acting injectable antipsychotics.
    Patel MX; Bent-Ennakhil N; Sapin C; di Nicola S; Loze JY; Nylander AG; Heres S
    BMC Psychiatry; 2020 Mar; 20(1):123. PubMed ID: 32169077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining long-acting injectable antipsychotic (depot) medication in the elderly: a five-year retrospective cross-sectional study evaluating depot use in an Australian psychogeriatric service.
    Doolabh U; Yeap S
    Australas Psychiatry; 2022 Feb; 30(1):31-36. PubMed ID: 34247547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical pharmacokinetics and pharmaceutical forms of long-acting injectable antipsychotics].
    Kyziridis TC
    Psychiatriki; 2022 Jun; 33(2):139-148. PubMed ID: 34390562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.